First lithographic results from the extreme ultraviolet Engineering Test Stand

The extreme ultraviolet ͑EUV͒ Engineering Test Stand ͑ETS͒ is a step-and-scan lithography tool that operates at a wavelength of 13.4 nm. It has been developed to demonstrate full-field EUV imaging and acquire system learning for equipment manufacturers to develop commercial tools. The initial integration of the tool is being carried out using a developmental set of projection optics, while a second, higher-quality, projection optics is being assembled and characterized in a parallel effort. We present here the first lithographic results from the ETS, which include both static and scanned resist images of 100 nm dense and isolated features throughout the ring field of the projection optics. Accurate lithographic models have been developed and compared with the experimental results

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial

Background: The PORTEC-3 trial investigated the benefit of combined adjuvant chemotherapy and radiotherapy versus pelvic radiotherapy alone for women with high-risk endometrial cancer. We updated the analysis to investigate patterns of recurrence and did a post-hoc survival analysis. // Methods: In the multicentre randomised phase 3 PORTEC-3 trial, women with high-risk endometrial cancer were eligible if they had International Federation of Gynaecology and Obstetrics (FIGO) 2009 stage I, endometrioid grade 3 cancer with deep myometrial invasion or lymphovascular space invasion, or both; stage II or III disease; or stage I–III disease with serous or clear cell histology; were aged 18 years and older; and had a WHO performance status of 0–2. Participants were randomly assigned (1:1) to receive radiotherapy alone (48·6 Gy in 1·8 Gy fractions given on 5 days per week) or chemoradiotherapy (two cycles of cisplatin 50 mg/m2 given intravenously during radiotherapy, followed by four cycles of carboplatin AUC5 and paclitaxel 175 mg/m2 given intravenously), by use of a biased coin minimisation procedure with stratification for participating centre, lymphadenectomy, stage, and histological type. The co-primary endpoints were overall survival and failure-free survival. Secondary endpoints of vaginal, pelvic, and distant recurrence were analysed according to the first site of recurrence. Survival endpoints were analysed by intention-to-treat, and adjusted for stratification factors. Competing risk methods were used for failure-free survival and recurrence. We did a post-hoc analysis to analyse patterns of recurrence with 1 additional year of follow-up. The study was closed on Dec 20, 2013; follow-up is ongoing. This study is registered with ISRCTN, number ISRCTN14387080, and ClinicalTrials.gov, number NCT00411138. // Findings: Between Nov 23, 2006, and Dec 20, 2013, 686 women were enrolled, of whom 660 were eligible and evaluable (330 in the chemoradiotherapy group, and 330 in the radiotherapy-alone group). At a median follow-up of 72·6 months (IQR 59·9–85·6), 5-year overall survival was 81·4% (95% CI 77·2–85·8) with chemoradiotherapy versus 76·1% (71·6–80·9) with radiotherapy alone (adjusted hazard ratio [HR] 0·70 [95% CI 0·51–0·97], p=0·034), and 5-year failure-free survival was 76·5% (95% CI 71·5–80·7) versus 69·1% (63·8–73·8; HR 0·70 [0·52–0·94], p=0·016). Distant metastases were the first site of recurrence in most patients with a relapse, occurring in 78 of 330 women (5-year probability 21·4%; 95% CI 17·3–26·3) in the chemoradiotherapy group versus 98 of 330 (5-year probability 29·1%; 24·4–34·3) in the radiotherapy-alone group (HR 0·74 [95% CI 0·55–0·99]; p=0·047). Isolated vaginal recurrence was the first site of recurrence in one patient (0·3%; 95% CI 0·0–2·1) in both groups (HR 0·99 [95% CI 0·06–15·90]; p=0·99), and isolated pelvic recurrence was the first site of recurrence in three women (0·9% [95% CI 0·3–2·8]) in the chemoradiotherapy group versus four (0·9% [95% CI 0·3–2·8]) in the radiotherapy-alone group (HR 0·75 [95% CI 0·17–3·33]; p=0·71). At 5 years, only one grade 4 adverse event (ileus or obstruction) was reported (in the chemoradiotherapy group). At 5 years, reported grade 3 adverse events did not differ significantly between the two groups, occurring in 16 (8%) of 201 women in the chemoradiotherapy group versus ten (5%) of 187 in the radiotherapy-alone group (p=0·24). The most common grade 3 adverse event was hypertension (in four [2%] women in both groups). At 5 years, grade 2 or worse adverse events were reported in 76 (38%) of 201 women in the chemoradiotherapy group versus 43 (23%) of 187 in the radiotherapy-alone group (p=0·002). Sensory neuropathy persisted more often after chemoradiotherapy than after radiotherapy alone, with 5-year rates of grade 2 or worse neuropathy of 6% (13 of 201 women) versus 0% (0 of 187). No treatment-related deaths were reported. // Interpretation: This updated analysis shows significantly improved overall survival and failure-free survival with chemoradiotherapy versus radiotherapy alone. This treatment schedule should be discussed and recommended, especially for women with stage III or serous cancers, or both, as part of shared decision making between doctors and patients. Follow-up is ongoing to evaluate long-term survival

Evaluating somatic cell scores with a Bayesian Gaussian linear state-space model.

Because accurate characterization of health state is important for managing dairy herds, we propose to validate the use of a linear state-space model (LSSM) for evaluating monthly somatic cell scores (SCSs). To do so, we retrieved SCS from a dairy database and collected reports on clinical mastitis collected in 20 farms, during the period from January 2008 to December 2011 in the Walloon region of Belgium. The dependent variable was the SCS, and the independent variables were the number of days from calving, year of calving and parity. The LSSM also incorporated an error-free underlying variable that described the trend across time as a function of previous clinical and subclinical status. We computed the mean sum of squared differences between observed SCS and median values of the posterior SCS distribution and constructed the receiver operating characteristic (ROC) curve for SCS thresholds going from 0 to 6. Our results show SCS estimates are close to observed SCS and area under the ROC curve is higher than 90%. We discuss the meaning of the parameters in light of our current knowledge of the disease and propose methods to incorporate, in LSSM, this knowledge often expressed in the form of ordinary differential equations

Risk factors of postpartum genital diseases in Holstein x Lai Sind crossbred cows in smallholdings, Ho Chi Minh City, Vietnam

A total of 353 calvings and postpartum periods of 302 Holstein x Lai Sind (HxLS) crossbred cows kept in 35 family farms in Cu Chi district, Ho Chi Minh City, Vietnam were observed to analyze the risk factors of retained placenta, dys­tocia and clinical endometritis. The cows were examined between day 21 post­partum and first service (109 days on average) by ultrasound and vaginoscopy. Dystocia prevalence was 1.7 higher in primiparous (29.9%) than in multipa­rous cows (20.4%) (p < 0.05). It was also six times higher in 2014 (40.6%) than in 2013 (10.1%) (odds ratio [OR] = 6.08; p < 0.001). Dystocia frequency was higher in the rainy season (30.4%) than in the dry season (17.0%) (OR = 2.14; p < 0.01). Prevalence of retained placenta was higher in 2014 (21.8%) than in 2013 (11.7%) (p < 0.01). Postpartum clinical endometritis was significantly higher in 2014 (28.6%) than in 2013 (11.7%) (OR = 3.03; p = 0.001), and in the rainy season (28.8%) than in the dry season (9.7%) (OR = 3.78; p < 0.001). Dys­tocia and retained placenta multiplied by 2.8 (p = 0.003) and 4.7 (p = 0.001), respectively, the risk of clinical endometritis